HLA-A*32:01 and Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms
JAMA Network Open · 02.09.2026 · 9 (9) · e2631291
DOI: 10.1001/jamanetworkopen.2026.31291 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 02.09.2026. Verfasst von Matthew S Krantz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Lamotrigine, Drug Hypersensitivity Syndrome, HLA-A Antigens, Anticonvulsants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, potentially fatal hypersensitivity syndrome with 3% to 10% mortality, and lamotrigine, a first-line treatment for bipolar and seizure disorders, is among the top 5 causative agents of DRESS in the United States and globally. Commercial panels test HLA-B*15:02 and HLA-A*31:01 for risk of carbamazepine-associated severe cutaneous adverse reactions; however, these are not validated for lamotrigine-induced DRESS, and current reports from these commercial assays could therefore provide false reassurance. No HLA associations with lamotrigine-induced DRESS have been established in US populations.
Objective
To identify HLA genetic variants associated with lamotrigine-induced DRESS in a US population. Design, Setting, and Participants This matched case-control study was conducted at 2 US academic medical centers (Vanderbilt University Medical Center and Mass General Brigham). Patients with lamotrigine-induced DRESS confirmed by Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria (score ≥4) were prospectively enrolled between April 2016 and June 2025. Lamotrigine-tolerant controls were matched 10:1 from the Vanderbilt BioVU biobank on sex, self-reported race, and age. HLA typing included class I ( HLA-A , HLA-B , and HLA-C ) and class II ( HLA-DPB1 , HLA-DQA1 , HLA-DQB1 , and HLA-DRB1 ) loci for case (high-resolution typing) and control (imputed from genotyping array data) participants. Main Outcomes and Measures HLA class I and II alleles and haplotypes were tested using logistic regression with Bonferroni correction for their association with lamotrigine-induced DRESS.
Results
This study included 29 patients with lamotrigine-induced DRESS (case participants; median [IQR] age, 33 [24-56] years; 25 female [86.2%]; 2 Asian [6.9%], 2 Black [6.9%], 23 White [79.3%], and 2 unknown race [6.9%]) and 290 matched control participants. HLA-A*32:01 was associated with lamotrigine-induced DRESS (41.4% [12 case participants] vs 4.1% [12 control participants]; odds ratio [OR], 16.4; 95% CI, 6.4-42.5; Bonferroni-corrected P < .001). No other alleles or class II loci showed significant associations after correction. The A*32:01 ~ B*44:02 haplotype was enriched (OR, 18.4; 95% CI, 4.6-83.8; Bonferroni-corrected P = .001) in lamotrigine-induced DRESS. Conclusions and Relevance In this case-control study, HLA-A*32:01 was associated with lamotrigine-induced DRESS in a US population. Given that HLA-A*32:01 is not included in existing commercial pharmacogenomic panels, adding this marker could improve preprescription DRESS risk identification for lamotrigine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of General Internal Medicine, Mass General Brigham, Somerville, Massachusetts.
- Department of Pediatrics, Mass General Brigham, Somerville, Massachusetts.
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville.
- Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville.
Zitieren
APA
Krantz, M. S., Zhou, L., Wang, L., Yu, A., Gangula, R., Ramirez-Valdez, E. A., Blackley, S., Ostrov, D. A., Li, D., Chopra, A., Mallal, S., Blumenthal, K., & Phillips, E. J. (2026). HLA-A*32:01 and Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms. JAMA Network Open, 9(9), e2631291. https://doi.org/10.1001/jamanetworkopen.2026.31291
Vancouver
Krantz MS, Zhou L, Wang L, Yu A, Gangula R, Ramirez-Valdez EA, et al. HLA-A*32:01 and Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms. JAMA Network Open. 2026;9(9):e2631291. doi:10.1001/jamanetworkopen.2026.31291
BibTeX
@article{Krantz2026,
author = {Krantz, Matthew S and Zhou, Li and Wang, Liqin and Yu, Alexis and Gangula, Rama and Ramirez-Valdez, Edric A and Blackley, Suzanne and Ostrov, David A and Li, Danmeng and Chopra, Abha and Mallal, Simon and Blumenthal, Kimberly and Phillips, Elizabeth J},
title = {HLA-A*32:01 and Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {9},
pages = {e2631291},
doi = {10.1001/jamanetworkopen.2026.31291}
}
EUVIMED